Business Context and Reporting Period
Company: Karyopharm Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 7, 2016
Event: Entry into a Material Definitive Agreement (Amendment No. 1 to Controlled Equity Offering Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It details a potential equity financing arrangement:
- Maximum Offering Size: Up to $50,000,000 in aggregate offering price.
- Security Type: Common stock, $0.0001 par value per share.
- Sales Agent: Cantor Fitzgerald & Co.
- Commission: Up to 3.0% of gross proceeds from the sale of shares.
- Method: "At the market" offering (Rule 415(a)(4)).
Material Changes Versus Prior Period
The filing represents an amendment to a Sales Agreement originally dated December 7, 2015. The material change is the authorization to issue and sell an additional aggregate offering price of up to $50,000,000 in shares on or after November 7, 2016. The filing text does not provide specific financial performance comparisons to prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The Company has no obligation to sell any shares in the Offering. Sales are determined by the Company from time to time.
- Termination Rights: Either the Company or Cantor Fitzgerald may suspend or terminate the offering upon notice to the other party.
- Legal Opinion: Wilmer Cutler Pickering Hale and Dorr LLP issued a legal opinion regarding the shares.
- Risks/Contingencies: The offering is subject to market conditions and the terms of the Sales Agreement. No specific operational risks or contingencies are detailed in this specific 8-K text beyond standard securities law disclaimers.
Important Facts for Investor Verification
- Verify the current share price to assess the potential dilution impact of a $50,000,000 offering.
- Confirm whether the Company has executed any sales under this amendment since November 7, 2016, as the filing only authorizes the potential sale.
- Review the full text of Amendment No. 1 (Exhibit 10.1) for specific conditions regarding the suspension or termination of the offering.
- Check subsequent filings to determine the actual gross proceeds raised and the net proceeds after the 3.0% commission.